4.20
0.08 (1.94%)
Previous Close | 4.12 |
Open | 4.31 |
Volume | 57,456 |
Avg. Volume (3M) | 138,945 |
Market Cap | 1,491,449,344 |
Price / Earnings (Forward) | 59.88 |
Price / Sales | 1.52 |
Price / Book | 1.31 |
52 Weeks Range | |
Earnings Date | 13 Aug 2025 |
Profit Margin | -26.26% |
Operating Margin (TTM) | -9.91% |
Diluted EPS (TTM) | -0.690 |
Quarterly Revenue Growth (YOY) | -4.20% |
Total Debt/Equity (MRQ) | 52.48% |
Current Ratio (MRQ) | 2.03 |
Operating Cash Flow (TTM) | 34.59 M |
Levered Free Cash Flow (TTM) | -90.11 M |
Return on Assets (TTM) | -2.42% |
Return on Equity (TTM) | -20.51% |
Market Trend
Short Term | Medium Term | ||
Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
Stock | Evotec SE | Mixed | Bearish |
AIStockmoo Score
Analyst Consensus | NA |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | 0.0 |
Technical Oscillators | -2.5 |
Average | -1.50 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States. |
|
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Investment Style | Small Core |
% Held by Institutions | 2.56% |
Ownership
Name | Date | Shares Held |
---|---|---|
Dcf Advisers, Llc | 31 Mar 2025 | 751,579 |
Abc Arbitrage Sa | 31 Mar 2025 | 77,919 |
Fore Capital, Llc | 31 Mar 2025 | 17,005 |
Quadrant Capital Group Llc | 31 Mar 2025 | 5,300 |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
06 Aug 2025 | Announcement | Evotec SE to announce first half-year results 2025 on 13 August 2025 |
30 Jul 2025 | Announcement | Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site |
30 Jul 2025 | Announcement | Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site |
21 Jul 2025 | Announcement | Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix |
21 Jul 2025 | Announcement | Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance |
25 Jun 2025 | Announcement | Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |